Evaxion Biotech A/S (EVAX)

USD 1.4

(-2.78%)

Market Cap (In USD)

442.15 Thousand

Revenue (In USD)

73.11 Thousand

Net Income (In USD)

-22.12 Million

Avg. Volume

2.39 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.8707-13.61
PE
-0.14
EPS
-10.0
Beta Value
-0.229
ISIN
US29970R2040
CUSIP
29970R105
CIK
1828253
Shares
315828.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Christian Kanstrup M.Sc.
Employee Count
-
Website
https://www.evaxion-biotech.com
Ipo Date
2021-02-05
Details
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.